

# William G Wierda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5916319/publications.pdf>

Version: 2024-02-01

179  
papers

25,137  
citations

9234

74  
h-index

6979

154  
g-index

180  
all docs

180  
docs citations

180  
times ranked

15394  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2013, 369, 32-42.	13.9	2,019
2	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 311-322.	13.9	1,532
3	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. <i>New England Journal of Medicine</i> , 2020, 382, 545-553.	13.9	1,252
4	Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 4079-4088.	0.8	899
5	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 323-332.	13.9	785
6	Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease. <i>Journal of Clinical Oncology</i> , 2012, 30, 488-496.	0.8	719
7	Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 768-778.	5.1	676
8	Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. <i>Blood</i> , 2008, 112, 975-980.	0.6	638
9	Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. <i>Blood</i> , 2015, 125, 2497-2506.	0.6	618
10	Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 826-833.	0.8	596
11	Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1749-1755.	0.8	541
12	Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 4070-4078.	0.8	480
13	Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. <i>Blood</i> , 2016, 127, 303-309.	0.6	441
14	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 48-58.	5.1	438
15	Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. <i>Blood</i> , 2008, 111, 5291-5297.	0.6	393
16	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. <i>Lancet</i> , The, 2020, 395, 1278-1291.	6.3	393
17	Ibrutinib and Venetoclax for First-Line Treatment of CLL. <i>New England Journal of Medicine</i> , 2019, 380, 2095-2103.	13.9	388
18	Chronic lymphocytic leukaemia. <i>Nature Reviews Disease Primers</i> , 2017, 3, 16096.	18.1	363

#	ARTICLE	IF	CITATIONS
19	Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. <i>Blood</i> , 2018, 131, 1910-1919.	0.6	339
20	CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. <i>Blood</i> , 2000, 96, 2917-2924.	0.6	318
21	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1090-1099.	5.1	315
22	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 65-75.	5.1	314
23	Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i> , 2007, 109, 4679-4685.	0.6	303
24	Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. <i>Blood</i> , 2015, 125, 2062-2067.	0.6	303
25	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. <i>Nature Communications</i> , 2016, 7, 11589.	5.8	285
26	Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. <i>Blood</i> , 2009, 114, 4441-4450.	0.6	284
27	High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurse-like cell cocultures and after BCR stimulation. <i>Blood</i> , 2009, 113, 3050-3058.	0.6	283
28	Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. <i>Blood</i> , 2008, 112, 1923-1930.	0.6	282
29	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet</i> , The, 2021, 397, 892-901.	6.3	260
30	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1973-1980.	0.8	257
31	Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. <i>Blood</i> , 2003, 101, 3413-3415.	0.6	247
32	Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. <i>Cancer Cell</i> , 2019, 36, 369-384.e13.	7.7	224
33	Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. <i>Cancer</i> , 2015, 121, 3612-3621.	2.0	220
34	Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2003, 98, 2657-2663.	2.0	203
35	Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2007, 110, 3316-3325.	0.6	203
36	Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. <i>Blood</i> , 2013, 122, 1891-1899.	0.6	184

#	ARTICLE	IF	CITATIONS
37	Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 3705-3715.	3.2	183
38	Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 1011-1019.	0.6	168
39	Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. <i>Blood</i> , 2009, 113, 4637-4645.	0.6	164
40	Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. <i>Blood</i> , 2011, 117, 3016-3024.	0.6	164
41	Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, 3489-3498.	0.6	161
42	Non-Hodgkin's Lymphomas. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 484-560.	2.3	161
43	Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. <i>Blood</i> , 2011, 118, 5126-5129.	0.6	152
44	De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. <i>Blood</i> , 2009, 114, 957-964.	0.6	150
45	Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 196-203.	0.8	145
46	Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. <i>Blood</i> , 2019, 134, 111-122.	0.6	145
47	Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 584-591.	0.8	137
48	Isoform-selective phosphoinositide 3-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. <i>Blood</i> , 2009, 113, 5549-5557.	0.6	135
49	Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. <i>Blood</i> , 2014, 123, 3727-3732.	0.6	133
50	Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. <i>Journal of Clinical Oncology</i> , 2017, 35, 166-174.	0.8	131
51	High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. <i>Blood</i> , 2003, 101, 4903-4908.	0.6	130
52	Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. <i>Leukemia and Lymphoma</i> , 2015, 56, 1643-1650.	0.6	130
53	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. <i>Blood</i> , 2020, 135, 1204-1213.	0.6	130
54	Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2018, 24, 4371-4379.	3.2	127

#	ARTICLE	IF	CITATIONS
55	Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 4088-4095.	0.8	124
56	Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. <i>Blood</i> , 2018, 131, 1704-1711.	0.6	122
57	Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 6450-6458.	0.6	121
58	Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. <i>Blood</i> , 2014, 123, 2783-2790.	0.6	119
59	Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3853-3865.	0.8	115
60	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1067-1079.	2.3	107
61	Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. <i>Clinical Cancer Research</i> , 2017, 23, 3734-3743.	3.2	106
62	Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. <i>Blood</i> , 2016, 127, 279-286.	0.6	105
63	Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. <i>Cancer</i> , 2017, 123, 2268-2273.	2.0	103
64	The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. <i>Blood</i> , 2008, 112, 711-720.	0.6	97
65	Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 156-164.	0.6	96
66	The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. <i>Leukemia and Lymphoma</i> , 2007, 48, 1931-1939.	0.6	92
67	Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. <i>Journal of Immunology</i> , 2017, 198, 1740-1747.	0.4	92
68	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. <i>Blood</i> , 2021, 138, 11-22.	0.6	90
69	Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. <i>Blood</i> , 2010, 115, 489-495.	0.6	86
70	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020, 135, 1859-1869.	0.6	86
71	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. <i>Cancer</i> , 2008, 113, 1933-1952.	2.0	84
72	A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2018, 132, 2249-2259.	0.6	84

#	ARTICLE	IF	CITATIONS
73	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. <i>Blood</i> , 2022, 139, 3278-3289.	0.6	83
74	Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. <i>Blood</i> , 2009, 113, 3168-3171.	0.6	82
75	Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, 2062-2068.	0.6	74
76	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 1171-1175.	3.3	72
77	Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment. <i>Journal of Clinical Oncology</i> , 2009, 27, 1637-1643.	0.8	71
78	Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. <i>Cancer</i> , 2019, 125, 559-574.	2.0	70
79	Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. <i>Blood</i> , 2022, 139, 1794-1806.	0.6	66
80	A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. <i>Cancer</i> , 2006, 106, 337-345.	2.0	65
81	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 2765-2775.	0.6	63
82	Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. <i>Haematologica</i> , 2014, 99, 1350-1355.	1.7	62
83	Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. <i>Leukemia</i> , 2021, 35, 3282-3286.	3.3	61
84	Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, 2085-2093.	0.6	56
85	Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2013, 119, 3805-3811.	2.0	56
86	NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 293-311.	2.3	55
87	Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 6325-6332.	0.8	53
88	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2021, 7, 1213.	3.4	53
89	Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. <i>Blood</i> , 2016, 128, 637-637.	0.6	48
90	Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2154-2158.	3.2	47

#	ARTICLE	IF	CITATIONS
91	Acalabrutinib in treatment-naive chronic lymphocytic leukemia. <i>Blood</i> , 2021, 137, 3327-3338.	0.6	47
92	Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years. <i>Leukemia Research</i> , 2010, 34, 284-288.	0.4	46
93	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 326-362.	2.3	46
94	Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. <i>Blood</i> , 2019, 134, 1951-1959.	0.6	45
95	Multiple-dose granulocyte-macrophage colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2008, 113, 383-387.	2.0	43
96	AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 3856-3867.	3.2	43
97	Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2004, 100, 2583-2591.	2.0	40
98	Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. <i>Blood</i> , 2018, 131, 1820-1832.	0.6	40
99	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. <i>Leukemia</i> , 2021, 35, 3059-3072.	3.3	40
100	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. <i>Blood</i> , 2019, 134, 35-35.	0.6	40
101	B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. <i>Molecular Cancer Research</i> , 2017, 15, 1692-1703.	1.5	38
102	Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. <i>British Journal of Haematology</i> , 2018, 182, 504-512.	1.2	37
103	Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. <i>Leukemia</i> , 2018, 32, 2388-2398.	3.3	34
104	NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 622-634.	2.3	33
105	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study. <i>Blood</i> , 2020, 136, 16-17.	0.6	32
106	Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 385-391.	0.2	31
107	LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. <i>Blood</i> , 2011, 117, 4076-4084.	0.6	28
108	Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 818-827.	1.0	28

#	ARTICLE	IF	CITATIONS
109	Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. <i>Clinical Cancer Research</i> , 2016, 22, 2359-2367.	3.2	28
110	Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2008, 112, 45-45.	0.6	28
111	Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2019, 187, 307-318.	1.2	26
112	What is the Best Frontline Therapy for Patients with CLL and 17p Deletion?. <i>Current Hematologic Malignancy Reports</i> , 2011, 6, 36-46.	1.2	24
113	Investigational Immunotherapeutics for B-Cell Malignancies. <i>Journal of Clinical Oncology</i> , 2010, 28, 884-892.	0.8	22
114	Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies. <i>Drugs</i> , 2019, 79, 1287-1304.	4.9	22
115	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. <i>Leukemia</i> , 2021, 35, 3421-3429.	3.3	22
116	Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 1424-1426.	0.6	21
117	Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL). <i>Journal of Clinical Oncology</i> , 2018, 36, 7502-7502.	0.8	21
118	Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. <i>Lancet Haematology</i> , 2020, 7, e168-e176.	2.2	20
119	Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. <i>Modern Pathology</i> , 2010, 23, 1518-1523.	2.9	19
120	Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. <i>British Journal of Haematology</i> , 2019, 185, 852-864.	1.2	19
121	Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial. <i>Blood</i> , 2009, 114, 207-207.	0.6	19
122	Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	19
123	$\hat{I}^2 <sub>2</sub>$ microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2016, 122, 565-573.	2.0	18
124	Initial Therapy for Patients With Chronic Lymphocytic Leukemia. <i>Seminars in Oncology</i> , 2006, 33, 202-209.	0.8	17
125	Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2011, 117, 116-124.	2.0	17
126	Ibrutinib: a paradigm shift in management of CLL. <i>Expert Review of Hematology</i> , 2014, 7, 705-717.	1.0	17

#	ARTICLE	IF	CITATIONS
127	Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells. <i>Blood</i> , 2014, 123, 3780-3789.	0.6	17
128	Current and Investigational Therapies for Patients with CLL. Hematology American Society of Hematology Education Program, 2006, 2006, 285-294.	0.9	16
129	Azacitidine in Fludarabine-Refractory Chronic Lymphocytic Leukemia: A Phase II Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 292-295.	0.2	16
130	Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. <i>Haematologica</i> , 2015, 100, e311-4.	1.7	15
131	Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. <i>Blood Advances</i> , 2020, 4, 4508-4511.	2.5	15
132	Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) Is Active for Relapsed and Refractory Patients with CLL. <i>Blood</i> , 2004, 104, 340-340.	0.6	15
133	Gene therapy and active immune therapy of hematologic malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 557-568.	0.7	14
134	Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. <i>Cancer</i> , 2015, 121, 3869-3876.	2.0	14
135	Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2015, 170, 40-49.	1.2	14
136	CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 1610-1620.	3.3	14
137	Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL. <i>Blood</i> , 2005, 106, 719-719.	0.6	14
138	Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). <i>British Journal of Haematology</i> , 2010, 148, 386-393.	1.2	13
139	Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. <i>Leukemia</i> , 2019, 33, 1663-1674.	3.3	13
140	Genetics and molecular biology of chronic lymphocytic leukemia. <i>Current Treatment Options in Oncology</i> , 2005, 6, 215-225.	1.3	12
141	Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. <i>British Journal of Haematology</i> , 2019, 185, 961-966.	1.2	12
142	Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2009, 114, 206-206.	0.6	12
143	An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2009, 114, 883-883.	0.6	12
144	Chronic lymphocytic leukemia. <i>Cancer</i> , 2009, 115, 3830-3841.	2.0	11

#	ARTICLE	IF	CITATIONS
145	Killing of Chronic Lymphocytic Leukemia by the Combination of Fludarabine and Oxaliplatin Is Dependent on the Activity of XPF Endonuclease. <i>Clinical Cancer Research</i> , 2011, 17, 4731-4741.	3.2	11
146	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. <i>Blood</i> , 2020, 136, 42-43.	0.6	11
147	The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 923-935.	1.5	11
148	Chronic Lymphocytic Leukemia: New Concepts for Future Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 369-378.	0.2	10
149	Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 828-833.	0.6	10
150	Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. <i>Oncolimmunology</i> , 2018, 7, e1417720.	2.1	10
151	Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019, 186, 184-188.	1.2	10
152	Clinical Efficacy of Lenalidomide in Fludarabine-Refractory Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2007, 110, 3108-3108.	0.6	10
153	Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase. <i>Haematologica</i> , 2022, 107, 292-297.	1.7	9
154	Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 921-921.	0.6	9
155	Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures. <i>Leukemia</i> , 2022, 36, 1324-1335.	3.3	9
156	Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2022, 36, 1596-1608.	3.3	9
157	Lenalidomide-Induced Graft-Vs.-Leukemia Effect in a Patient With Chronic Lymphocytic Leukemia Who Relapsed After Allogeneic Stem Cell Transplant. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e105-e109.	0.2	8
158	PET-positive lymphadenopathy in CLL "Not always Richter transformation. <i>American Journal of Hematology</i> , 2017, 92, 405-406.	2.0	8
159	A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. <i>British Journal of Haematology</i> , 2019, 185, 606-608.	1.2	8
160	Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T cell chimerism is associated with high relapse risk and inferior survival. <i>British Journal of Haematology</i> , 2017, 177, 567-577.	1.2	7
161	Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. <i>Leukemia and Lymphoma</i> , 2018, 59, 1427-1438.	0.6	7
162	Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. <i>Leukemia and Lymphoma</i> , 2021, 62, 1129-1135.	0.6	6

#	ARTICLE	IF	CITATIONS
163	A phase III trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. <i>Oncotarget</i> , 2017, 8, 22104-22112.	0.8	6
164	TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. <i>American Journal of Hematology</i> , 2022, 97, 1005-1012.	2.0	6
165	Updates to the Management of Chronic Lymphocytic Leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 662-665.	2.3	5
166	Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets. <i>Blood Cancer Journal</i> , 2022, 12, 43.	2.8	5
167	The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. <i>British Journal of Haematology</i> , 2019, 187, e1-e4.	1.2	4
168	RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. <i>Leukemia</i> , 2022, 36, 712-722.	3.3	4
169	Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 348-356.	0.6	3
170	Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2018, 32, 2278-2281.	3.3	3
171	Immunologic monitoring in chronic lymphocytic leukemia. <i>Current Oncology Reports</i> , 2003, 5, 419-425.	1.8	2
172	Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2021, 194, 61-68.	1.2	2
173	Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. <i>Leukemia and Lymphoma</i> , 2022, , 1-9.	0.6	2
174	Chronic Lymphocytic Leukemia: How to Assess Prognosis in 2007. <i>Clinical Leukemia</i> , 2007, 1, 162-167.	0.2	1
175	Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL). <i>Journal of Blood Medicine</i> , 2010, 1, 115.	0.7	1
176	High-Risk Acute Myeloid Leukemia: A Pediatric Prospective. <i>Biomedicines</i> , 2022, 10, 1405.	1.4	1
177	New aspects of the treatment of chronic lymphocytic leukemia. <i>Current Hematologic Malignancy Reports</i> , 2006, 1, 251-257.	1.2	0
178	HLA Homozygosity and Haplotype Bias Among Patients with Chronic Lymphocytic Leukemia: Implications for Disease Control by Physiologic Immune Surveillance. <i>Blood</i> , 2010, 116, 1370-1370.	0.6	0
179	Ibrutinib Plus Venetoclax for First-Line Chronic Lymphocytic Leukemia Treatment. , 0, , .		0